SeaStar Medical Q2 FY26 net loss widens to $3.7 million; revenue rises 82% to $0.6 million - ICU News | RalliesSeaStar Medical Q2 FY26 net loss widens to $3.7 million; revenue rises 82% to $0.6 million
I
ICU• Clinical trial update
- NEUTRALIZE-AKI adult trial reached 223 of 339 patients.
- Enrollment completion is targeted around year-end or Q1 2027, with PMA filing eyed near end-2027.
Q2 results and operating trends
- SeaStar Medical posted Q2 net loss of $3.7 million, or $0.91 per share, widening from a year earlier.
- Net revenue rose 82% year over year to $615,000, driven by higher QUELIMMUNE demand and three new children’s hospital customers.
- Gross margin slipped 1 percentage point to 91%, while R&D expense climbed to $2.52 million on higher trial costs.
- Cash fell to $7 million at June 30 from $12 million at year-end 2025.
